Based on 4 analysts giving stock ratings to Adial Pharmaceuticals Inc in the past month.
In the current month, ADIL has received 3 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. ADIL average Analyst price target in the last month is 8.333.
Based on analysts' estimates, ADIL EPS is projected to reach -0.633 in FY2026Q4, following reported EPS of -4.516 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
The market expectation was USD -4.52, while Adial Pharmaceuticals IncADIL's earnings per share (EPS) for the previous quarter was USD -11.25. EPS for the next quarter is expected at USD -0.63.